These are top 10 stocks traded on the Robinhood UK platform in July
Solid Biosciences Inc. (NASDAQ:SLDB) recently reported that its Chief Financial Officer and Treasurer, Kevin Tan, executed a series of stock transactions. According to the SEC Form 4 filing, Tan sold 3,164 shares of common stock on February 14, 2025, at a price of $3.96 per share, resulting in a total transaction value of $12,529. The stock has since risen to $5.30, marking a significant 22% gain over the past week, according to InvestingPro data.
The filing also detailed that Tan acquired 10,625 shares of common stock on February 13, 2025, through the vesting of restricted stock units, which were granted at no cost. This acquisition increased his direct ownership to 35,414 shares following the transactions. With a market capitalization of $212 million, InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 7.85, though it faces profitability challenges.
The sale was made to cover withholding taxes following the vesting of these restricted stock units, as per a pre-established sales instruction letter. This transaction was not a discretionary trade by Tan, as noted in the filing. While the stock shows recent positive momentum, investors should note that InvestingPro has identified 11 additional key insights about the company’s financial health and market position.
In other recent news, Solid Biosciences reported positive initial clinical data from its next-generation Duchenne gene therapy candidate, SGT-003. The company also announced the pricing of an underwritten offering of shares and pre-funded warrants, aiming to raise approximately $200 million. Analysts from Truist and JMP Securities have recognized the potential of SGT-003, with Truist assigning a Buy rating and $16 price target on Solid Biosciences’ stock.
The U.S. Food and Drug Administration (FDA) granted Fast Track designation to Solid Biosciences for its gene therapy candidate SGT-212, aimed at treating Friedreich’s ataxia, a serious genetic neurodegenerative disease. The company plans to begin a Phase 1b trial for SGT-212 in the second half of 2025.
These are recent developments for Solid Biosciences, a company advancing a diverse pipeline of gene therapy candidates for rare diseases. The company’s efforts are closely monitored by investors and stakeholders, particularly the progress of its ongoing INSPIRE DUCHENNE trial and the upcoming SGT-212 trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.